Alexion Pharmaceuticals

Alexion Pharmaceuticals, now the rare disease unit of AstraZeneca, is a global biopharmaceutical company specializing in the development of life-changing therapies for patients with rare and devastating conditions. The company is a pioneer in complement biology, having developed Soliris and Ultomiris, the first approved treatments for paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome. Alexion's portfolio also includes enzyme replacement therapies for metabolic disorders and treatments for rare neurological conditions like generalized myasthenia gravis. Following its $39 billion acquisition by AstraZeneca in 2021, Alexion continues to lead innovation in immunology and rare disease medicine. The company maintains a robust pipeline focused on hematology, nephrology, neurology, and metabolic diseases.